Molecular genetic pathways to Wilms tumor

Critical Reviews in Oncogenesis

Volumn 8, Issue 1, 1997, Pages 1-27

  Pritchard Jones, Kathryn ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Childhood cancer genetics; Nephrogenesis; WT1

Indexed keywords

MESSENGER RNA; SOMATOMEDIN B; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIRIDIA; APOPTOSIS; BECKWITH WIEDEMANN SYNDROME; CARCINOGENESIS; CELL CYCLE; CHROMOSOME 11P; DENYS DRASH SYNDROME; GENE LOCUS; GENE MUTATION; HUMAN; KIDNEY DEVELOPMENT; MENTAL DEFICIENCY; MOLECULAR GENETICS; NEPHROBLASTOMA; NONHUMAN; REVIEW; SYNDROME; TUMOR SUPPRESSOR GENE; UROGENITAL TRACT MALFORMATION;

EID: 0031425396     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v8.i1.10     Document Type: Review

References (203)

1. Adachi, Y., S. Matsubara, C. Pedraza, M. Ozawa, J. I. Tsutsui, H. Takamatsu, H. Noguchi, T. Akiyama, and T. Muramatsu: Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1). Oncogene, 13:2197-2203 (1996).
2. Akasaka, Y., H. Kikuchi, T. Nagai, N. Hiraoka, S. Kato, and J. Hata: A point mutation found in the WT1 gene in a sporadic Wilms' tumor without genitourinary abnormalities is identical with the most frequent point mutation in Denys-Drash syndrome. FEBS Lett., 317:39-43 (1993).
3. Alders, M., J. Bliek, B. Redeker, et al.: Cloning of candidate genes involved in the Beckwith-Wiedemann syndrome and childhood tumours. Med. Pediatr. Oncol., 27:495-497 (1996).
4. Algar, E. M., T. Khromykh, S. I. Smith, D. M. Blackburn, G. J. Bryson, and P. J. Smith: A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene, 12:1005-1014 (1996).
5. Baird, P. N., N. Groves, D. A. Haber, D. E. Housman, and J. K. Cowell: Identification of mutations in the WT1 gene in tumours from patients with the WAGR syndrome. Oncogene, 7:2141-2149 (1992).
6. Bardeesy, N., J. B. Beckwith, and J. Pelletier: Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations. Cancer Res., 55:215-219 (1995).
7. Bardeesy, N., D. Falkoff, M. J. Petruzzi, N. Nowak, B. Zabel, M. Adam, M. C. Aguiar, P. Grundy, T. Shows, and J. Pelletier: Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat. Genet., 7:91-97 (1994).
8. Beckwith, J. B., N. B. Kiviat, and J. F. Bonadio: Nephrogenic rests, nephroblastomatosis and the pathogenesis of Wilms tumour. Pediatr. Pathol., 10: (1990).
9. Bickmore, W. A., K. Oghene, M. H. Little, A. Seawright, V. Van Heyningen, and N. D. Hastie: Modulation of DNA binding specificity by alternative splicing of the Wilms tumor wt 1 gene transcript. Science, 257:235-237 (1992).
10. Blatt, J., R. Jaffe, M. Deutsch, and J. C. Adkins: Neurofibromatosis and childhood tumors. Cancer, 57:1225-1229 (1986).
11. Breslow, N., A. Olshan, J. B. Beckwith, and D. Green: Epidemiology of Wilms tumor. Med. Pediatr. Oncol., 21:172-181 (1993).
12. Breslow, N. E., J. Olson, J. Moksness, J. B. Beckwith, and P. Grundy: Familial Wilms tumour: a descriptive study. Med. Pediatr. Oncol., 27:398-403 (1996).
13. Brown, K. W., J. E. Watson, V. Poirier, M. G. Mott, P. J. Berry, and N. J. Maitland: Inactivation of the remaining allele of the WT1 gene in a Wilms tumour from a WAGR patient. Oncogene, 7:763-768 (1992).
14. Brown, K. W., H. P. Wilmore, J. E. Watson, M. G. Mott, P. J. Berry, and N. J. Maitland: Low frequency of mutations in the WT1 coding region in Wilms' tumor. Genes Chromosome Cancer, 8:74-79 (1993).
15. Bruening, W., N. Bardeesy, B. L. Silverman, R. A. Cohn, G. A. Machin, A. J. Aronson, D. Housman, and J. Pelletier: Germline intronic and exonic mutations in the Wilms tumour gene (WT1) affecting urogenital development. Nat. Genet., 1:144-148 (1992).
16. Bruening, W. and J. Pelletier: A non-AUG translational initiation event generates novel WT1 isoforms. J. Biol. Chem., 271:8646-8654 (1996).
17. Call, K. M., T. Glaser, C. Y. Ito, A. J. Buckler, J. Pelletier, D. A. Haber, E. A. Rose, A. Kral, H. Yeger, W. H. Lewis, C. Jones, and D. E. Housman: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell, 60:509-520 (1990).
18. Campbell, C. E., A. Huang, A. L. Gurney, P. M. Kessler, J. A. Hewitt, and B. R. Williams: Antisense transcripts and protein binding motifs within the Wilms tumour (WT1) locus. Oncogene, 9:583-95 (1994).
19. Caricasole, A., A. Duarte, S. H. Larsson, N. D. Hastie, M. Little, G. Holmes, I. Todorov, and A. Ward: RNA binding by the Wilms tumor suppressor zinc finger proteins. Proc. Natl. Acad. Sci. U.S.A., 93:7562-7566 (1996).
20. Casola, S., P. V. Pedone, A. O. Cavazzana, G. Basso, R. Luksch, E. S. G. Damore, M. Carli, C. B. Bruni, and A. Riccio: Expression and parental imprinting of the H19 gene in human rhabdomyosarcoma. Oncogene, 14:1503-1510 (1997).
21. Chandra, M. and W. W. Carlton: Incidence, histopathologic and electron microscopic features of spontaneous nephroblastomas in rats. Toxicol. Lett., 62:179-190 (1992).
22. Chao, L. Y., V. Huff, G. Tomlinson, V. M. Riccardi, L. C. Strong, and G. F. Saunders: Genetic mosaicism in normal tissues of Wilms' tumour patients. Nat. Genet., 3:127-131 (1993).
23. Clericuzio, C. L.: Clinical phenotypes and Wilms tumor. Med. Pediatr. Oncol., 21:182-187 (1993).
24. Cohen, H. T., S. A. Bossone, G. Zhu, G. A. McDonald, and V. P. Sukhatme: Spl is a critical regulator of the Wilms' tumor-1 gene. J. Biol. Chem., 272:2901-2913 (1997).
25. Cook, D. M., M. T. Hinkes, M. Bernfield, and F. J. Rauscher, III: Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1. Oncogene, 13:1789-1799(1996).
26. Coppes, M. J., C. E. Campbell, and B. R. Williams: The role of WT1 in Wilms tumorigenesis. FASEB J., 7:886-895 (1993a).
27. Coppes, M. J., G. J. Liefers, P. Paul, H. Yeger, and B. R. Williams: Homozygous somatic WT1 point mutations in sporadic unilateral Wilms tumor. Proc. Natl. Acad. Sci. U.S.A., 90:1416-1419 (1993b).
28. Cowell, J., R. Wadey, D. Haber, K. Call, D. Housman, and J. Pritchard: Structural rearrangements of the WT1 gene in Wilms' tumour cells. Oncogene, 6:595-599 (1991).
29. Davies, J. A. and A. W. Brandli. (1997). The Kidney Development Database, http://www.ana.ed.ac.uk/anatomy/database/kidbase/kidhome.html.
30. DeChiara, M., A. Efstratiadis, and E. J. Robertson: A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene distrupted by targeting. Nature, 345:78-80 (1990).
31. Dehbi, M., M. Ghahremani, M. Lechner, G. Dressier, and J. Pelletier: The paired-box transcription factor, PAX2, positively modulates expression of the Wilms' tumor suppressor gene (WT1). Oncogene, 13:447-453 (1996).
32. Dehbi, M. and J. Pelletier: PAX8-mediated activation of the wtl tumor suppressor gene. EMBO J., 15:4297-4306 (1996).
33. Demoor, C. H., M. Jansen, E. J. Bonte, A. Thomas, J. S. Sussenbach, and J. L. Vandenbrande: Influence of the four leader sequences of the human IGF2 mRNAs on the expression of reporter genes. Eur. J. Biochem., 226:1039-1047 (1994).
34. Dey, B. R., V. P. Sukhatme, A. B. Roberts, M. B. Sporn, F. J. Rauscher, III, and S. J. Kim: Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product. Mol. Endocrinol., 8:595-602 (1994).
35. Dowdy, S. F., C. L. Fasching, D. Araujo, K. M. Lai, E. Livanos, B. E. Weissman, and E. J. Stanbridge: Suppression of tumorigenicity in Wilms tumor by the p15.5-p14 region of chromosome 11. Science, 254: 293-295 (1991).
36. Drummond, I. A., S. L. Madden, P. Rohwer-Nutter, G. I. Bell, V. P. Sukhatme, and F. J. Rauscher III: Repression of the insulin-like growth factor II gene by the Wilms tumour suppressor WT1. Science, 257:674-678 (1992).
37. Drummond, I. A., H. D. Rupprecht, N. P. Rohwer, G. J. Lopez, S. L. Madden, F. J. Rauscher, III, and V. P. Sukhatme: DNA recognition by splicing variants of the Wilms' tumor suppressor, WT1. Mol. Cell. Biol., 14:3800-3809 (1994).
38. Ekstrom, T. J., H. Cui, X. Li, and R. Ohlsson: Promoter-specific IGF2 imprinting status and its plasticity during human liver development. Development, 121: 309-316 (1995).
39. Englert, C., X. Hou, S. Maheswaran, P. Bennett, C. Ngwu, G. G. Re, A. J. Garvin, M. R. Rosner, and D. A. Haber: WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J., 14:4662-4675 (1995a).
40. Englert, C., S. Maheswaran, A. J. Garvin, J. Kreidberg, and D. A. Haber: Induction of p21 by the Wilms' tumor suppressor gene WT1. Cancer Res., 57:1429-1434 (1997).
41. Englert, C., M. Vidai, S. Maheswaran, Y. Ge, R. M. Ezzell, K. J. Isselbacher, and D. A. Haber: Truncated WT1 mutants alter the subnuclear localization of the wild-type protein. Proc. Natl. Acad. Sci. U.S.A., 92:11960-11964 (1995b).
42. Fantes, J. A., W. A. Bickmore, J. M. Fletcher, F. Ballesta, I. M. Hanson, and V. Van Heyningen: Submicroscopic deletions at the WAGR locus, revealed by nonradioactive in situ hybridization. Am. J. Hum. Genet., 51:1286-1294 (1992).
43. Ferguson-Smith, A. C.: Imprinting moves to the centre. Nat. Genet., 14:119-121 (1996).
44. Fong, A. T., R. H. Dashwood, R. Cheng, C. Mathews, B. Ford, J. D. Hendricks, and G. S. Bailey: Carcinogenicity, metabolism and Ki-ras proto-oncogene activation by 7,12-dimethylbenz(a)anthracene in rainbow trout embryos. Carcinogenesis, 14:629-635 (1993).
45. Fraizer, G. C., Y. J. Wu, S. M. Hewitt, T. Maity, C. C. Ton, V. Huff, and G. F. Saunders: Transcriptional regulation of the human Wilms' tumor gene (WT1). Cell type-specific enhancer and promiscuous promoter. J. Biol. Chem., 269:8892-8900 (1994).
46. Garvin, A. J., G. G. Re, B. I. Tarnowski, M. D. Hazen, and D. A. Sens: The G401 cell line, utilized for studies of chromosomal changes in Wilms' tumor, is derived from a rhabdoid tumor of the kidney. Am. J. Pathol., 142:375-380 (1993).
47. German, J.: Bloom's syndrome. XX. The first 100 cancers. Cancer Genet. Cytogenet., 93:100-106 (1997).
48. Gessler, M., A. Konig, K. Arden, P. Grundy, S. Orkin, S. Sallan, C. Peters, S. Ruyle, J. Mandell, F. Li, W. Cavenee, and G. Bruns: Infrequent mutation of the WT1 gene in 77 Wilms' tumors. Hum. Mutat., 3:212-222 (1994).
49. Gessler, M., A. Konig, J. Moore, S. Qualman, K. Arden, W. Cavenee, and G. Brans: Homozygous inactivation of WT1 in a Wilms' tumor associated with the WAGR syndrome. Genes Chromosome Cancer, 7:131-136 (1993).
50. Gessler, M., A. Poustka, W. Cavenee, R. L. Neve, S. H. Orkin, and G. A. P. Bruns: Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature, 343:774-778 (1990).
51. Gillis, A. J., J. W. Oosterhuis, M. E. Schipper, E. J. Barten, B. R. van, G. R. van, M. Abraham, G. F. Saunders, and L. H. Looijenga: Origin and biology of a testicular Wilms' tumor. Genes Chromosome Cancer, 11:126-135 (1994).
52. Glaser, T., J. Lane, and D. E. Houseman: A mouse model of the aniridia-Wilms tumour deletion syndrome. Science, 250:823-827 (1990).
53. Goodyer, P., M. Dehbi, E. Torban, W. Bruening, and J. Pelletier: Repression of the retinoic acid receptor-alpha gene by the Wilms' tumor suppressor gene product, wt1. Oncogene, 10:1125-1129 (1995).
54. Greenberg, F., K. Copeland, and M. Gresik: Expanding the spectrum of Perlman syndrome. Am. J. Med. Genet., 29:773-776 (1988).
55. Grundy, P., A. Koufos, K. Morgan, F. P. Li, A. T. Meadows, and W. K. Cavenee: Familial predisposition to Wilms tumor does not map to the short arm of chromosome 11. Nature, 336:374-376 (1988).
56. Grundy, P., P. Telzerow, J. Moksness, and N. E. Breslow: Clinicopathologic correlates of loss of heterozygosity in Wilms' tumor: a preliminary analysis. Med. Pediat. Oncol., 27:429-433 (1996).
57. Grundy, P. E., P. E. Telzerow, N. Breslow, J. Moksness, V. Huff, and M. C. Paterson: Loss of heterozygosity for chromosomes 16q and Ip in Wilms' tumors predicts an adverse outcome. Cancer Res., 54:2331-2333 (1994).
58. Gunning, K. B., S. L. Cohn, G. E. Tomlinson, L. C. Strong, and V. Huff: Analysis of possible abnormal WT1 RNA processing in primary Wilms tumors. Oncogene, 13: 1179-1185 (1996).
59. Haber, D. A., A. J. Buckler, T. Glaser, K. M. Call, J. Pelletier, R. L. Sohn, E. C. Douglass, and D. E. Housman: An internal deletion within a 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell, 61:1257-1269 (1990).
60. Haber, D. A., S. Park, S. Maheswaran, C. Englert, G. G. Re, M. D. Hazen, D. A. Sens, and A. J. Garvin: WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science, 262:2057-2059 (1993).
61. Haber, D. A., H. T. M. Timmers, J. Pelletier, P. A. Sharp, and D. E. Housman: A dominant mutation in the Wilms tumor gene WT1 cooperates with the viral oncogene E1 A in transformation of primary kidney cells. Proc. Natl. Acad. Sci. U.S.A., 89:6010-6014 (1992).
62. Hamel, B., M. Mannes, and J. Bokkerink: Perlman syndrome: a report of a case and results of molecular studies. Am. J. Hum. Genet., 45:A48 (1990).
63. Hamilton, T. B., K. C. Barilla, and P. J. Romaniuk: High-affinity binding sites for the Wilms' tumour suppressor protein WT1. Nucleic Acids Res., 23:277-284 (1995).
64. Hao, Y., T. Crenshaw, T. Moulton, E. Newcomb, and B. Tycko: Tumour suppressor activity of H19 RNA. Nature, 365:764-767 (1993).
65. Harrington, M. A., B. Konicek, A. Song, X. L. Xia, W. J. Fredericks, and F. J. Rauscher, III: Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. J. Biol. Chem., 268:21271-21275 (1993).
66. Hartley, A. L., J. M. Birch, K. Tricker, S. A. Wallace, A. M. Kelsey, M. Harris, and P. H. Jones: Wilms' tumor in the Li-Fraumeni cancer family syndrome. Cancer Genet. Cytogenet., 67:133-135 (1993).
67. Hastie, N. D.: The genetics of Wilms' tumor - a case of disrupted development. Annu. Rev. Genet., 28:523-558 (1994).
68. Hatada, I., H. Ohashi, Y. Fukushima, Y. Kaneko, M. Inoue, Y. Komoto, A. Okada, S. Ohishi, A. Nabetani, H. Morisaki, M. Nakayama, N. Niikawa, and T. Mukai: An imprinted gene p57(KIP2) is mutated in Beckwith-Wiedemann syndrome. Nat. Genet., 14:171-173 (1996).
69. Hewitt, S. M., G. C. Fraizer, Y. J. Wu, F. J. Rauscher, III, and G. F. Saunders: Differential function of Wilms' tumor gene WT1 splice isoforms in transcriptional regulation. J. Biol. Chem., 271:8588-8592 (1996).
70. Hewitt, S. M., S. Hamada, T. J. McDonnell, F. J. Rauscher III, and G. F. Saunders: Regulation of the protooncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res., 55:5386-5389 (1995).
71. Hewitt, S. M. and G. F. Saunders: Differentially spliced exon 5 of the Wilms' tumor gene WT1 modifies gene function. Anticancer Res., 16:621-626 (1996).
72. Hino, O., H. Mitani, and A. G. Knudson: Genetic predisposition to transplacentally induced renal cell carcinomas in the Eker rat. Cancer Res., 53:5856-5858 (1993).
73. Hoovers, J. M. N., L. M. Kalikin, L. A. Johnson, M. Alders, B. Redeker, D. J. Law, J. Bliek, M. Steenman, M. Benedict, J. Wiegant, C. Lengauer, P. Taillon-Miller, D. Schlessinger, M. C. Edwards, S. J. Elledge, A. Ivens, A. Westerveld, P. Little, M. Mannens, and A. P. Feinberg: Multiple genetic loci within 11p15 defined by Beckwith-Wiedemann syndrome rearrangement breakpoints and subchromosomal transferable fragments. Proc. Natl. Acad. Sci. U.S.A., 92:12456-12460 (1995).
74. Huang, A., C. E. Campbell, L. Bonetta, M. S. McAndrews-Hill, S. Chilton-MacNeill, M. J. Coppes, D. J. Law, A. P. Feinberg, H. Yeger, and B. R. G. Williams: Tissue, developmental and tumor-specific expression of divergent transcripts in Wilms tumor. Science, 250:991-994 (1990).
75. Huff, V.: Genotype/phenotype correlations in Wilms' tumor. Med. Pediatr. Oncol., 27:408-414 (1996).
76. Huff, V., C. I. Amos, E. C. Douglass, R. Fisher, C. F. Geiser, C. E. Klill, F. P. Li, L. C. Strong, and J. M. McDonald: Evidence for genetic heterogeneity in familial Wilms' tumor. Cancer Res., 57:1859-1862 (1997).
77. Huff, V., N. Jaffe, G. F. Saunders, L. C. Strong, F. Villalba, and E. C. Ruteshouser: WT1 exon 1 deletion/insertion tmitutions in Wilms tumor patients, associated with di-and trinucleotide repeats and deletion hotspot consensus sequences. Am. J. Hum. Genet., 56:84-90 (1995).
78. Huff, V., A. E. Reeve, M. Leppert, L. C. Strong, E. C. Douglass, C. F. Geiser, F. P. Li, A. Meadows, D. F. Callen, G. Lenoir, and G. F. Saunders: Nonlinkage of 16q markers to familial predisposition to Wilms tumour. Cancer Res., 52:6117-6120 (1992).
79. Hughes-Benzie, R. M., G. Pilia, J. Y. Xuan, A. G. W. Hunter, E. Chen, M. Golabi, J. A. Hurst, J. Kobori, K. Marymee, R. A. Pagon, H. H. Punnett, S. Schelley, J. L. Tolmie, M. M. Wohlferd, T. Grossman, D. Schlessinger, and A. E. MacKenzie: Simpson-GolabiBehmel syndrome: genotype/phenotype analysis of 18 affected males from 7 unrelated families. Am. J. Med. Genet., 66:227-234 (1996).
80. Jadresic, L., J. Leake, I. Gordon, M. J. Dillon, D. B. Grant, J. Pritchard, R. A. Risdon, and T. M. Barratt: Clinicopathologic review of twelve children with nephropathy, Wilms tumor, and genital abnormalities (Drash syndrome). J. Pediatr., 117:717-725 (1990).
81. Jinno, Y., K. Yun, K. Nishiwaki, T. Kubota, O. Ogawa, A. E. Reeve, and N. Niikawa: Mosaic and polymorphic imprinting of the WT1 gene in humans. Nat. Genet., 6:305-309 (1994).
82. Johnstone, R. W., R. H. See, S. F. Sells, J. Wang, S. Muthukkumar, C. Englert, D. A. Haber, J. D. Licht, S. P. Sugrue, T. Roberts, V. M. Rangnekar, and Y. Shi: A novel represser, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol. Cell. Biol., 16:6945-6956 (1996).
83. Kakinuma, A., I. Morimoto, Y. Nakano, R. Fujimoto, O. Ishida, Y. Okada, N. Inokuchi, T. Fujihira, and S. Eto: Familial primary hyperparathyroidism complicated with Wilms' tumor. Intern. Med., 33:123-126 (1994).
84. Kamb, A., N. A. Gruis, J. Weaver-Feldhaus, Q. Liu, K. Harshman, S. V. Tavtigian, E. Stocken, R. S. Day, III, B. E. Johnson, and M. H. Skolnick: A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264:436 (1994).
85. Kaneko, Y., O. Takeda, C. Homma, N. Maseki, H. Miyoshi, Y. Tsunematsu, B. G. Williams, G. F. Saunders, and M. Sakurai: Deletion of WT1 and WIT1 genes and loss of heterozygosity on chromosome 11p in Wilms tumors in Japan. Jpn. J. Cancer Res., 84:616-624 (1993).
86. Kaplinsky, C., M. Ghahremani, Y. Frishberg, G. Rechavi, and J. Pelletier: Familial Wilms' tumor associated with a WT1 zinc finger mutation. Genomics, 38:451-453 (1996).
87. Kennedy, D., T. Ramsdale, J. Mattick, and M. Little: An RNA recognition motif in Wilms' tumour protein (WT1) revealed by structural modelling. Nat. Genet., 12:329-332 (1996).
88. Kent, J., A. M. Coriat, P. T. Sharpe, N. D. Hastie, and V. van Heyningen: The evolution of WT1 sequence and expression pattern in the vertebrates. Oncogene, 11:1781-1792 (1995).
89. Kent, J., M. Lee, A. Schedl, S. Boyle, J. Fantes, M. Powell, N. Rushmere, C. Abbott, V. van Heyningen, and W. A. Bickmore: The reticulocalbin gene maps to the WAGR region in human and to the small eye Harwell deletion in mouse. Genomics, 42:260-267 (1997).
90. Kikuchi, H., Y. Akasaka, T. Nagai, A. Umezawa, H. Iri, S. Kato, and J. I. Hata: Genomic changes in the WT-gene (WT1) in Wilms' tumors and their correlation with histology. Am. J. Pathol., 140:781-786 (1992).
91. Kinane, T. B., J. D. Finder, A. Kawashima, D. Brown, M. Abbate, W. J. Fredericks, V. P. Sukhatme, F. J. Rauscher, III, and L. Ercolani: LLC-PK1 cell growth is repressed by WT1 inhibition of G-protein alpha(i-2) protooncogene transcription. J. Biol. Chem., 270:30760-30764 (1995).
92. Knudson, A. G. and L. C. Strong: Mutation and cancer: a model for Wilms tumour of the kidney. J. Natl. Cancer Inst., 48:313-324 (1972).
93. Konig, A., S. Jakubiczka, P. Wieacker, H. W. Schlosser, and M. Gessler: Further evidence that imbalance of WT1 isoforms may be involved in Denys-Drash syndrome. Hum. Mol. Genet., 2:1967-1968 (1993).
94. Koseki, C., D. Herzlinger, and Q. Al-Awqati: Apoptosis in metanephric development. J. Cell Biol., 119:1327-1333 (1992).
95. Koufos, A., P. Grundy, K. Morgan, K. A. Aleck, T. Hadro, B. C. Lampkin, A. Kalbakji, and W. K. Cavenee: Familial Wiedemann-Beckwith syndrome and a second Wilms tumour locus both map to 11p15.5. Am. J. Hum. Genet., 44:711-719 (1989).
96. Kreidberg, J. A., H. Sariola, J. M. Loring, M. Maeda, J. Pelletier, D. Housman, and R. Jaenisch: WT-1 is required for early kidney development. Cell, 74:679-691 (1993).
97. Kudoh, T., T. Ishidate, M. Moriyama, K. Toyoshima, and T. Akiyama: G1 phase arrest induced by Wilms tumor protein WT1 is abrogated by cyclin/CDK complexes. Proc. Natl. Acad. Sci. U.S.A., 92:4517-4521 (1995).
98. Kudoh, T., T. Ishidate, T. Nakamura, K. Toyoshima, and T. Akiyama: Constitutive expression of the Wilms tumor suppressor gene WT1 in F9 embryonal carcinoma cells induces apoptotic cell death in response to retinoic acid. Oncogene, 13:1431-1439 (1996).
99. Larsson, S. H., J. P. Charlieu, K. Miyagawa, D. Engelkamp, M. Rassoulzadegan, A. Ross, F. Cuzin, H. V. van, and N. D. Hastie: Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell, 81:391-401 (1995).
100. Lassus, P., M. Ferlin, J. Piette, and U. Hibner: Anti-apoptotic activity of low levels of wild-type p53. EMBO J., 15:4566-4573 (1996).
101. Law, M. H., E. Algar, and M. Little: Allelic imbalance at chromosome 1q21 in Wilms tumor. Cancer Genet. Cytogenet., 97:54-59 (1997).
102. Lee, M. P., R. J. Hu, L. A. Johnson, and A. P. Feinberg: Human KVLQT1 gene shows tissue-specific imprinting and encompasses Beckwith-Wiedemann syndrome chromosomal rearrangements. Nat. Genet., 15:181-185 (1997a).
103. Lee, M. P., DeBaun, M., Randhawa, G., Reichard, B. A., Elledge, S. J., and Feinberg, A. P.: Low frequency of p57KIP2 mutation in Beckwith-Wiedemann syndrome. Am. J. Hum. Genet., 61:304-309 (1997b).
104. Leighton, P. A., J. R. Saam, R. S. Ingram, C. L. Stewart, and S. M. Tilghman: An enhancer deletion affects both H19 and Igf2 expression. Genes Dev., 9:2079-2089 (1995).
105. Li, F. P., N. E. Breslow, J. M. Morgan, M. Ghahremani, G. A. Miller, P. E. Grundy, D. M. Green, L. R. Diller, and J. Pelletier: Germline WT1 mutations in Wilms' tumor patients: preliminary results. Med. Ped. Oncol., 27:404-407 (1996).
106. Lindsay, S., M. Ireland, O. Obrien, J. ClaytonSmith, J. A. Hurst, J. Mann, T. Cole, J. Sampson, S. Slaney, D. Schlessinger, J. Burn, and G. Pilia: Large-scale deletions in the GPC3 gene may account for a minority of cases of Simpson-Golabi-Behmel syndrome. J. Med. Genet., 34:480-483 (1997).
107. Little, M. and C. Wells: A clinical overview of Wt1 gene mutations. Hum. Mut., 9:209-225 (1997).
108. Little, M. H., R. Dunn, J. A. Byrne, A. Seawright, P. J. Smith, K. Pritchard-Jones, V. Van Heyning, and N. D. Hastie: Equivalent expression of paternally and maternally inherited WT1 alleles in normal fetal tissue and Wilms' tumours. Oncogene, 7:635-641 (1992a).
109. Little, M. H., G. Holmes, L. Pell, A. Caricasole, A. Duarte, M. Law, A. Ward, and B. Wainwright: A novel target for the Wilms' tumour suppressor protein (WT1) is bound by a unique combination of zinc fingers. Oncogene, 13:1461-1469 (1996).
110. Little, M. H., J. Presser, A. Condie, P. J. Smith, V. Van Heyningen, and N. D. Hastier Zinc finger point mutations within the WT1 gene in Wilms tumor patients. Proc. Natl. Acad, Sci. U.S.A., 89:4791-4795 (1992b).
111. Little, M. H., K. A. Williamson, M. Mannens, A. Kelsey, C. Gosden, N. D. Hastie, and H. V. van: Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion. Hum. Mol. Genet., 2:259-264 (1993).
112. Liu, J.-P., J. Baker, A. S. Perkins, E. J. Robertson, and A. Efstratiadis: Mice carrying null mutations of the genes encoding insulin-like growth factor 1 (1gf-1) and type 1 IGF receptor (1gf1r). Cell, 75:59-72 (1993).
113. Madden, S. L., D. M. Cook, and F. D. Rauscher: A structure-function analysis of transcriptional repression mediated by the WT1, Wilms' tumor suppressor protein. Oncogene, 8:1713-1720 (1993).
114. Maheswaran, S., C. Englert, P. Bennett, G. Heinrich, and D. A. Haber: The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev., 9:2143-2156 (1995).
115. Maheswaran, S., S. Park, A. Bernard, J. F. Morris, F. D. Rauscher, D. E. Hill, and D. A. Haber: Physical and functional interaction between WT1 and p53 proteins. Proc. Natl. Acad. Sci. U.S.A., 90:5100-5104 (1993).
116. Malik, K. T., J. I. Wallace, S. M. Ivins, and K. W. Brown: Identification of an antisense WT1 promoter in intron 1: implications for WT1 gene regulation. Oncogene, 11:1589-1595 (1995).
117. Mannens, M., J. M. Hoovers, E. Redeker, M. Verjaal, A. P. Feinberg, P. Little, M. Boavida, N. Coad, M. Steenman, J. Bliek, et al.: Parental imprinting of human chromosome region 11p15.3-pter involved in the Beckwith-Wiedemann syndrome and various human neoplasia. Eur. J. Hum. Genet., 2:3-23 (1994).
118. Martinerie, C., G. Chevalier, F. J. Rauscher III, and B. Perbal: Regulation of no v by WT1: a potential role for nov in nephrogenesis. Oncogene, 12:1479-1492 (1996).
119. Martinerie, C., V. Huff, I. Joubert, M. Badzioch, G. Saunders, L. Strong, and B. Perbal: Structural analysis of the human nov proto-oncogene and expression in Wilms tumor. Oncogene, 9:2729-2732 (1994).
120. Matsuoka, S., J. S. Thompson, M. C. Edwards, J. M. Barletta, P. Grundy, L. M. Kalikin, J. W. Harper, S. J. Elledge, and A. P. Feinberg: Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57(KIP2), on chromosome 11p15. Proc. Natl Acad. Sci. U.S.A., 93:3026-3030 (1996).
121. McCann, S., J. Sullivan, J. Guerra, M. Arcinas, and L. M. Boxer: Repression of the c-myb gene by WT1 protein in T and B cell lines. J. Biol. Chem., 270:23785-23789 (1995).
122. McConnell, M. J., H. E. Cunliffe, L. J. Chua, T. A. Ward, and M. R. Eccles: Differential regulation of the human Wilms tumour suppressor gene (WT1) promoter by two isoforms of PAX2. Oncogene, 14:2689-2700 (1997).
123. Menke, A. L., N. Riteco, R. C. A. Van Ham, C. De Bruyne, F. J. Rauscher, III, A. J. Van der Eb, and A. G. Jochemsen: Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells. Oncogene, 12:537-546 (1996).
124. Mierau, G. W. and J. B. Beckwith: Ultrastructure and histogenesis of the renal tumours of childhood: an overview. Ultrastructural Pathol., 11:313-333 (1987).
125. Miozzo, M., D. Perotti, F. Minoletti, P. Mondini, S. Pilotti, R. Luksch, F. Fossati-Bellani, M. A. Pierotti, G. Sozzi, and P. Radice: Mapping of a putative tumor suppressor locus to proximal 7p in Wilms tumors. Genomics, 37:310-315 (1996).
126. Moffett, P., W. Bruening, H. Nakagama, N. Bardeesy, D. Housman, D. E. Housman, and J. Pelletier: Antagonism of WT1 activity by protein self-association. Proc. Natl. Acad. Sci. U.S.A., 92:11105-11109 (1995).
127. Moshier, J. A., M. Skunca, W. Wu, S. M. Boppana, F. J. Rauscher, III, and J. Dosescu: Regulation of ornithine decarboxylase gene expression by the Wilms' tumor suppressor WT1. Nucl. Acids Res., 24:1149-1157 (1996).
128. Moulton, T., W. Y. Chung, L. Yuan, T. Hensle, P. Waber, P. Nisen, and B. Tycko: Genomic imprinting and Wilms' tumor. Med. Pediatr. Oncol., 27:476-483 (1996).
129. Moulton, T., T. Crenshaw, Y. Hao, J. Moosikasuwan, N. Lin, F. Dembitzer, T. Hensle, L. Weiss, L. McMorrow, T. Loew, W. Kraus, W. Gerald, and B. Tycko: Epigenetic lesions at the H19 locus in Wilms' tumour patients. Nat. Genet., 7:440-447 (1994).
130. Murata, Y., T. Kudoh, H. Sugiyama, K. Toyoshima, and T. Akiyama: The Wilms tumor suppressor gene WT1 induces G1 arrest and apoptosis in myeloblastic leukemia Ml cells. FEBS Lett., 409:41-45 (1997).
131. Nagata, M., H. Nakauchi, K. I. Nakayama, K. Nakayama, D. Loh, and T. Watanabe: Apoptosis during an early stage of nephrogenesis induces renal hypoplasia in bcl-2-deficient mice. Am. J. Pathol., 148:1601-1611 (1996).
132. Nakagama, H., G. Heinrich, J. Pelletier, and D. E. Housman: Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product. Mol. Cell. Biol., 15:1489-1498 (1995).
133. Nichols, K. E., G. G. Re, Y. X. Yan, A. J. Garvin, and D. A. Haber: WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells. Cancer Res., 55:4540-4543 (1995).
134. Nordenskjold, A., E. Friedman, B. Sandstedt, S. Soderhall, and M. Anvret: Constitutional and somatic mutations in the WT1 gene in Wilms' tumor patients. Int. J. Cancer, 63:516-522 (1995).
135. Ogawa, O., D. M. Becroft, I. M. Morison, M. R. Eccles, J. E. Skeen, D. C. Mauger, and A. E. Reeve: Constitutional relaxation of insulin-like growth factor II gene imprinting associated with Wilms' tumour and gigantism. Nat. Genet., 5:408-412 (1993a).
136. Ogawa, O., M. R. Eccles, J. Szeto, L. A. McNoe, K. Yun, M. A. Maw, P. J. Smith, and A. E. Reeve: Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature, 362:749-751 (1993b).
137. Ohgaki, H., P. Kleihues, and G. C. Hard: Ki-ras mutations in spontaneous and chemically induced renal tumors of the rat. Mol. Carcinogen., 4:455-459 (1991).
138. KIP2 are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms tumours. Am. J. Hum. Genet., 61:295-303 (1997).
139. Park, S., A. Bernard, K. E. Bove, D. A. Sens, M. D. Hazen, A. J. Garvin, and D. A. Haber: Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour. Nat. Genet., 5:363-367 (1993a).
140. Park, S., G. Tomlinson, P. Nisen, and D. A. Haber: Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor. Cancer Res., 53:4757-4760 (1993b).
141. Pelletier, J., W. Bruening, C. E. Kashtan, S. M. Mauer, J. C. Manivel, J. E. Striegel, D. C. Houghton, C. Junien, R. Habib, L. Fouser, R. N. Fine, B. L. Silverman, D. A. Haber, and D. Housman: Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell, 67:437-447 (1991a).
142. Pelletier, J., W. Bruening, F. P. Li, D. A. Haber, T. Glaser, and D. E. Housman: WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. Nature, 353:431-434 (1991b).
143. Perantoni, A. O., L. F. Dove, and I. Karavanova: Basic fibroblast growth factor can mediate the early inductive events in renal development. Proc. Natl. Acad. Sci. U.S.A., 92:4696-4700 (1995).
144. Pichel, J. G., L. Shen, H. Z. Sheng, A. C. Granholm, J. Drago, A. Grinberg, E. J. Lee, S. P. Huang, M. Saarma, B. J. Hoffer, H. Sariola, and H. Westphal: Defects in enteric innervation and kidney development in mice lacking GDNF. Nature, 382:73-76 (1996).
145. Pilia, G., R. M. HughesBenzie, A. MacKenzie, P. Baybayan, E. Y. Chen, R. Huber, G. Neri, A. Cao, A. Forabosco, and D. Schlessinger: Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat. Genet., 12:241-247 (1996).
146. Poleev, A., F. Wendler, H. Fickenscher, M. S. Zannini, K. Yaginuma, C. Abbott, and D. Plachov: Distinct functional properties of three human paired-box-protein, PAX8, isoforms generated by alternative splicing in thyroid, kidney and Wilms' tumors. Eur. J. Biochem., 228:899-911 (1995).
147. Poukka, H., P. J. Kallio, O. A. Janne, and J. J. Palvimo: Regulation of the rat p75 neurotrophin receptor promoter by GC element binding proteins. Biochem. Biophys. Res. Com., 229:565-570 (1996).
148. Pritchard-Jones, K.: Mutations in the Wilms tumour gene, WT1. What do they mean? Eur. J. Cancer, 31A:2138-2140 (1995).
149. Pritchard-Jones, K. and S. Fleming: Cell types expressing the Wilms tumour gene (WT1) in Wilms tumours: implications for tumour histogenesis. Oncogene, 6:2211-2220 (1991).
150. Pritchard-Jones, K., L. King-Underwood, N. Rahman, S. Variend, and M. Gerard: Familial Wilms tumour is heterogeneous and may involve the WT1 gene. Med. Pediatr. Oncol., 29:338 (Abstr. O79) (1997).
151. Rahman, N., L. Arbour, P. Tonin, J. Renshaw, J. Pelletier, S. Baruchel, K. Pritchard-Jones, M. R. Stratton, and S. A. Narod: Evidence for a familial Wilms' tumour gene (FWT1) on chromosome 17q12- q21. Nat. Genet., 13:461-463 (1996).
152. Rainier, S., L. A. Johnson, C. J. Dobry, A. J. Ping, P. E. Grundy, and A. P. Feinberg: Relaxation of imprinted genes in human cancer. Nature, 362:747-749 (1993).
153. Rauscher, F. J., II: The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. FASEB J., 7:896-903 (1993).
154. Reddy, J. C., S. Hosono, and J. D. Licht: The transcriptional effect of WT1 is modulated by choice of expression vector. J. Biol. Chem., 270:29976-29982 (1995a).
155. Reddy, J. C. and J. D. Licht: The WT1 Wilms' tumor suppressor gene: how much do we really known? Biochim. Biophys. Acta - Reviews on Cancer, 1287:1-28 (1996).
156. Reddy, J. C., J. C. Morris, J. Wang, M. A. English, D. A. Haber, Y. Shi, and J. D. Licht: WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins. J. Biol. Chem., 270:10878-10884 (1995b).
157. Reid, L. H., A. West, D. G. Gioeli, K. K. Phillips, K. F. Kelleher, D. Araujo, E. J. Stanbridge, S. F. Dowdy, D. S. Gerhard, and B. E. Weissman: Localization of a tumor suppressor gene in 11p15.5 using the G401 Wilms' tumor assay. Hum. Mol. Genet., 5:239-247 (1996).
158. Renshaw, J., L. King-Underwood, and K. Pritchard-Jones: Differential splicing of exon 5 of the Wilms tumour (WT1) gene. Genes Chromosome Cancer, 19:256-266 (1997).
159. Reynolds, P. A., R. M. Powlesland, T. J. Keen, C. F. Inglehearn, A. F. Cunningham, E. D. Green, and K. W. Brown: Localization of a novel t(1;7) translocation associated with Wilms' tumor predisposition and skeletal abnormalities. Genes Chromosome Cancer, 17: 151-155 (1996).
160. Roberts, D. J., D. Haber, J. Sklar, and C. P. Crum: Extrarenal Wilms' tumors. A study of their relationship with classic renal Wilms' tumor using expression of WT1 as a molecular marker. Lab. Invest., 68:528-536 (1993).
161. Royer-Pokora, B., S. Ragg, B. Heckl-Ostreicher, M. Held, U. Loos, K. Call, T. Glaser, D. Housman, G. Saunders, B. Zabel, B. Williams, and A. Poustka: Direct pulsed field gel electrophoresis of Wilms' tumors shows that DNA deletions in 11p13 are rare. Genes Chromosome Cancer, 3:89-100 (1991).
162. Rupprecht, H. D., I. A. Drummond, S. L. Madden, F. J. Rauscher III, and V. P. Sukhatme: The Wilms' tumor suppressor gene WT1 is negatively autoregulated. J. Biol. Chem., 269:6198-6206 (1994).
163. Ryan, G., P. V. Steele, J. F. Morris, F. R. Rauscher, and G. R. Dressier: Repression of Pax-2 by WT1 during normal kidney development. Development, 121:867-875 (1995).
164. Sainio, K., P. Hellstedt, J. A. Kreidberg, L. Saxen, and H. Sariola: Differential regulation of two sets of mesonephric tubules by WT1. Development, 124:1293-1299 (1997).
165. Santos, A., A. L. Osorio, P. N. Baird, J. M. Silva, M. G. Boavida, and J.
166. Sawyer, J. R., E. W. Winkel, J. F. Redman, and G. J. Roloson: Translocation (7;7)(p13;q21) in a Wilms' tumor. Cancer Genet. Cytogenet., 69:57-59 (1993).
167. Saxen, L.: Organogenesis of the Kidney. Cambridge University Press (1987).
168. Scharnhorst, V., O. Kranenburg, A. J. Van der Eb, and A. G. Jochemsen: Differential regulation of the Wilms' tumor gene, WT1, during differentiation of embryonal carcinoma and embryonic stem cells. Cell Growth Differ., 8:133-143 (1997).
169. Schuchardt, A., V. D'Agati, L. Larsson-Blomerg, F. Costantini, and V. Pachnis: Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature, 367:380-383 (1994).
170. Schumacher, V., S. Schneider, A. Figge, G. Wildhardt, D. Harms, D. Schmidt, A. Weirich, R. Ludwig, and B. Royer-Pokora: Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. Proc. Natl. Acad Sci. U.S.A., 94:3972-3977 (1997).
171. Sells, S. F., S. S. Man, S. Muthukkumar, N. Maddiwar, R. Johnstone, E. Boghaert, D. Gillis, G. Liu, P. Nair, S. Monnig, P. Collini, M. P. Mattson, V. P. Sukhatme, S. G. Zimmer, Wood Dp, Jr., J. W. McRoberts, Y. Shi, and V. M. Rangnekar: Expression and function of the leucine zipper protein par-4 in apoptosis. Mol. Cell. Biol., 17:3823-3832(1997).
172. Sharma, P. M., M. Bowman, S. L. Madden, F. R. Rauscher, and S. Sukumar: RNA editing in the Wilms' tumor susceptibility gene, WT1. Genes Dev., 8:720-731 (1994a).
173. Sharma, P. M., M. Bowman, B. F. Yu, and S. Sukumar: A rodent model for Wilms tumors: Embryonal kidney neoplasms induced by N-nitroso-N′-methylurea. Proc. Natl. Acad. Sci. U.S.A., 91:9931-9935 (1994b).
174. Sharpe, C. R. and E. L. Franco: Etiology of Wilms tumour. Epidemiologic Reviews, 17:415-432 (1995).
175. Simms, L. A., E. M. Algar, and P. J. Smith: Splicing of exon 5 in the WT1 gene is disrupted in Wilms' tumour. Eur. Jr Cancer Part A, 31:2270-2276 (1995).
176. Song, H. H., W. Shi, and J. Filmus: OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. J. Biol. Chem., 272:7574-7577 (1997).
177. Sotelo-Avila, C., F. Gonzalez-Crussi, and J. W. Fowler: Complete and incomplete forms of Beckwith-Wiedemann syndrome: their oncogenic potential. J. Pediatr., 96:47-50 (1980).
178. Stark, K., S. Vainio, G. Vassileva, and A. P. McMahon: Epithelial transformation of metanephric mesenchyme in the developing kidney regulated by Wnt-4. Nature, 372:679-683 (1994).
179. Steenman, M. J., S. Rainier, C. J. Dobry, P. Grundy, I. L. Horon, and A. P. Feinberg: Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat. Genet., 7:433-439 (1994).
180. Szabo, J., B. Heath, V. M. Hill, C. E. Jackson, R. J. Zarbo, L. E. Mallette, S. L. Chew, G. M. Besser, R. V. Thakker, V. Huff, M. F. Lepperts, and H. Heath III: Hereditary hyperparathyroidism-jaw tumour syndrome: the endocrine tumour gene HRPT2 maps to chromosome 1q21-q31. Am. J. Hum. Genet., 56:944-950 (1995).
181. Tadokoro, K., H. Fujii, A. Ohshima, Y. Kakizawa, K. Shimizu, A. Sakai, K. Sumiyoshi, T. Inoue, Y. Hayashi, and M. Yamada: Intragenic homozygous deletion of the WT1 gene in Wilms' tumor. Oncogene, 7:1215-1221 (1992).
182. Taniguchi, T., K. Okamoto, and A. E. Reeve: Human p57(KIP2) defines a new imprinted domain on chromosome lip but is not a tumour suppressor gene in Wilms tumour. Oncogene, 14:1201-1206 (1997).
183. Taniguchi, T., M. J. Sullivan, O. Ogawa, and A. E. Reeve: Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms tumor. Proc. Natl. Acad. Sci. U.S.A., 92:2159-2163 (1995).
184. Thompson, J. S., K. J. Reese, M. R. DeBaun, E. J. Perlman, and A. P. Feinberg: Reduced expression of the cyclin-dependent kinase inhibitor gene p57(KIP2) in Wilms' tumor. Cancer Res., 56:5723-5727 (1996).
185. Torres, M., E. Gomez-Pardo, G. R. Dressler, and P. Gruss: Pax 2 controls multiple steps of urogenital development. Development, 121:4057-4065 (1995).
186. Van Heyningen, V., W. A. Bickmore, A. Seawright, J. M. Fletcher, J. Maule, G. Fekete, M. Gessler, G. A. P. Bruns, C. Huerre-Pierre, C. Junien, B. R. G. Williams, and N. D. Hastie: Role for the Wilms' tumour gene in genital development? Proc. Natl. Acad. Sci. U.S.A., 82:5383-5386 (1990).
187. Varanasi, R., N. Bardeesy, M. Ghahremani, M. J. Petruzzi, N. Nowak, M. A. Adam, P. Grundy, T. B. Shows, and J. Pelletier: Fine structure analysis of the WT1 gene in sporadic Wilms tumors. Proc. Natl. Acad. Sci. U.S.A., 91:3554-3558 (1994).
188. Wang, Z. Y., Q. Q. Qiu, K. T. Enger, and T. F. Deuel: A second transcriptionally active DNA-binding site for the Wilms tumor gene product, WT1. Proc. Natl. Acad. Sci. U.S.A., 90:8896-8900 (1993).
189. Wang, Z. Y., Q. Q. Qiu, M. Gurrieri, J. Huang, and T. F. Deuel: WT1, the Wilms' tumor suppressor gene product, represses transcription through an interactive nuclear protein. Oncogene, 10:1243-1247 (1995a).
190. Wang, Z. Y., Q. Q. Qiu, J. Huang, M. Gurrieri, and T. F. Deuel: Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wtl, have altered DNA binding specificity and regulate transcription in different ways. Oncogene, 10:415-422 (1995b).
191. Wang, Z. Y., Q. Q. Qiu, W. Seufert, T. Taguchi, J. R. Testa, S. A. Whitmore, D. F. Callen, D. Welsh, T. Shenk, and T. F. Deuel: Molecular cloning of the cDNA and chromosome localization of the gene for human ubiquitin-conjugating enzyme 9. J. Biol. Chem., 271:24811-24816 (1996).
192. Weksberg, R., S. Ding Ren, F. Yan Ling, S. Qian Li, and J. Squire: Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome. Nat. Genet., 5:143-150 (1993).
193. Werner, H., F. J. Rauscher, III, V. P. Sukhatme, I. A. Drummond, C. J. Roberts, and D. LeRoith: Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site. J. Biol. Chem., 269:12577-12582 (1994).
194. Werner, H., Z. Shen Orr, F. J. Rauscher, III, J. F. Morris, C. T. Roberts, Jr., and D. LeRoith: Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol. Cell. Biol., 15:3516-3522 (1995).
195. Wiedemann, H. R.: Tumours and hemihypertrophy associated with Wiedemann-Beckwith syndrome. Eur. J. Paediatr., 141:129 (1983).
196. Wilkins, R. J.: Genomic imprinting and carcinogenesis. Lancet, i:329-330 (1988).
197. Williamson, K. A.: Involvement of the WT1 and p16 genes in Wilms tumour and human malignant mesothelioma. Ph.D thesis Edinburgh University. (1996).
198. Woolf, A. S., M. Kolatsi-Joannou, P. Hardman, E. Andermarcher, C. Moorby, L. G. Fine, P. S. Jat, M. D. Noble, and E. Gherardi: Roles of hepatocye growth factor/scatter factor and the met receptor in the early development of the metanephros. J. Cell Biol., 128:171-184 (1995).
199. Wrana, J. L.: H19, a tumour suppressing RNA? Bioessays, 16:89-90 (1994).
200. Xu, Y., P. Grundy and C. Polychronakos: Aberrant imprinting of the insulin-like growth factor II receptor gene in Wilms' tumor. Oncogene, 14:1041-1046 (1997).
201. Yamagami, T., H. Sugiyama, K. Inoue, H. Ogawa, T. Tatekawa, M. Hirata, T. Kudoh, T. Akiyama, A. Murakami, T. Maekawa, and T. Kishimoto: Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: Implications for the involvement of WT1 in leukemogenesis. Blood, 87:2878-2884 (1996).
202. Ye, Y., B. Raychaudhuri, A. Gurney, C. E. Campbell, and B. R. G. Williams: Regulation of WT1 by phosphorylation: inhibition of DNA binding, alteration of transcriptional activity and cellular translocation. EMBO J., 15:5606-5615 (1996).
203. Zhang, P., N. J. Llegeois, C. Wong, M. Finegold, H. Hou, J. C. Thompson, A. Silverman, J. W. Harper, R. A. DePinho, and S. J. Elledge: Altered cell differentiation and proliferation in mice lacking p57(KIP2) indicates a role in Beckwith-Wiedemann syndrome. Nature, 387:151-158 (1997).